The E2F4 prognostic signature predicts pathological response to neoadjuvant chemotherapy in breast cancer patients

BACKGROUND: Neoadjuvant chemotherapy is a key component of breast cancer treatment regimens and pathologic complete response to this therapy varies among patients. This is presumably due to differences in the molecular mechanisms that underlie each tumor’s disease pathology. Developing genomic clini...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:BMC Cancer
Autori principali: Mark, Kenneth M. K., Varn, Frederick S., Ung, Matthew H., Qian, Feng, Cheng, Chao
Natura: Artigo
Lingua:Inglês
Pubblicazione: BioMed Central 2017
Soggetti:
Research Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5414335/
https://ncbi.nlm.nih.gov/pubmed/28464832
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-017-3297-2
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi